ClinicalTrials.gg
CompletedNCT02406092Updated Nov 21, 2024Results posted

Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

A Phase 3 interventional study of Rituximab and Cyclophosphamide in Non-Hodgkin Lymphoma, sponsored by Hoffmann-La Roche. Completed at 13 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
139
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 178 studies testing rituximab in Lymphoma, Non-Hodgkin — 5 open to participants now, 11 under way, 2 of them phase 3. Rituximab · Lymphoma, Non-Hodgkin.

Enrollment
32nd of 171
139 · median 38
Started
2015
with 5 others
Phase 3
29 of 178
none open now
Registered
151st of 178
by date
Lead sponsor
13 of 178
Hoffmann-La Roche

Among the 178 studies testing rituximab in Lymphoma, Non-Hodgkin, this one is the 32nd largest by enrollment of the 171 interventional ones that give a count, is one of 6 that started in 2015, is one of 29 in phase 3, and was the 151st registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

5 of the 178 studies testing rituximab in Lymphoma, Non-Hodgkin are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 178 studies testing rituximab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).

03

Conditions studied

  • Non-Hodgkin Lymphoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, cluster of differentiation (CD)20+ DLBCL or CD20+ follicular NHL grade 1 to 3a, according to the world health organization (WHO) classification system
  • Currently being treated with rituximab IV in the Induction or Maintenance setting, having received at least one full dose of rituximab IV, defined as standard full dose of rituximab IV 375 milligrams per square meter (mg/m\^2) administered without interruption or early discontinuation because of tolerability issues
  • Expectation and current ability for the participants to receive at least four additional cycles of treatment during the Induction phase or six additional cycles of treatment during the Maintenance phase (participants with follicular NHL)

Exclusion criteria

Exclusion Criteria:

  • Transformed lymphoma or FL IIIB
  • History of other that could affect compliance with the protocol or interpretation of results. This includes a malignancy that has been treated but not with curative intent, unless the malignancy has been in remission without treatment for greater than or equal to (>/=) 5 years prior to dosing
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
139 participants (actual)

Study arms

  • Experimental
    Rituximab

    Participants with FL and DLBCL will receive rituximab SC 1400 milligrams (mg) once a month for a minimum of 4 cycles as induction therapy. Participants with FL will continue to receive rituximab once in 2 months for a minimum of 6 cycles as maintenance therapy according to local standards of care. Participants will also receive standard chemotherapy regimen (CHOP \[cyclophosphamide+doxorubicin+vincristine+prednisone\], CVP \[cyclophosphamide+vincristine+prednisone\] or FC \[fludarabine+cyclophosphamide\]) during induction.

    Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone · Drug: Fludarabine

Interventions

  • Rituximab SC 1400 mg

    Also known as: MabThera®

  • Cyclophosphamide will be administered as per standard local practice.

    Also known as: Endoxan

  • Doxorubicin will be administered as per standard local practice.

  • Vincristine will be administered as per standard local practice.

  • Prednisone will be administered as per standard local practice.

  • Fludarabine will be administered as per standard local practice.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Administration-Associated Reactions (AARs)

    AARs defined as all related adverse events (AEs) occurring within 24 hours of rituximab SC administration, including infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof.

    Time frame: Within 24 hours of each rituximab SC administration (maximum treatment duration up to 32 months for FL participants and up to 8 months for DLBCL participants)

Secondary outcomes

  1. Event-Free Survival (EFS) as Assessed by Investigator According to International Working Group (IWG) Response Criteria

    EFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first dose of SC) to first occurrence of progression or relapse, according to the IWG response criteria or other country standards, or initiation of a non-protocolspecified anti-lymphoma therapy or death, whichever occurs first.

    Time frame: From first dose of rituximab intravenous (IV) and SC until first occurrence of progression or relapse (up to end of induction treatment [Up to 53.8 Months])

  2. Progression-Free Survival (PFS) as Assessed by Investigator According to IWG Response Criteria

    PFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first dose of SC) to the first occurrence of progression or relapse, according to the IWG response criteria (Cheson et al. 1999) or other country standards, or death from any cause.

    Time frame: From first dose of rituximab IV and SC until first occurrence of progression or relapse (up to end of induction treatment [Up to 53.8 Months])

  3. Overall Survival (OS)

    OS is defined as the time from first dose of rirtuximab (analysed using both first dose of IV and first dose of SC) until death from any cause.

    Time frame: From first dose of rituximab IV and SC until death from any cause (up to end of induction treatment [Up to 51.1 Months])

  4. Disease-Free Survival (DFS) as Assessed by Investigator According to IWG Response Criteria

    DFS will be assessed at the end of induction treatment in patients achieving CR/CRu and is defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause.

    Time frame: From the date of the initial complete response (CR)/complete response unconfirmed (CRu) until date of relapse or death from any cause (up to end of induction treatment [Up to 32.7 Months])

  5. Percentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria

    CR/CRu: Response assessments 4 - 6 weeks after the last dose of induction treatment will be based on the Investigator's assessment, completed according to the original International Working Group (IWG) response criteria for response assessment of lymphoma (Cheson et al. 1999).

    Time frame: From first dose of rituximab until first occurrence of progression or relapse (up to end of induction treatment [Up to 32 Months])

  6. Healthcare Professional Questionnaire Score

    Planned Healthcare Professional Questionnaiere was not collected during the study therefore no data to report

    Time frame: End of treatment (Month 24 for FL participants and Month 8 for DLBCL participants)

  7. Patient-Reported Rituximab Administration Questionnaire (RASQ) Score

    The RASQ measures the overall participant satisfaction and is a 20-item questionnaire measuring the impact of the treatment administration on 5 domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each question's answer is chosen from 1 (minimum)-5(maximum score indicating less severity) score range. For each domain was scored using the following formula: Domain score = \[(Sum of completed item (question) responses / Number of completed items) - 1\] x 100 / (Maximum possible item response value - Minimum possible item response value) The final RASQ domains is calculated using the formula: RASQ domain score = (Mean of completed item responses - 1) x 25, scores ranging from 1-100 with higher scores indicative of more positive feelings toward therapy. Lower number representing lower satisfaction and higher is the higher satisfaction by the participants.

    Time frame: Up to 53.8 Months

07

Results

Posted Nov 21, 2024

Participant flow

Total of 139 participants mentioned below in the table were recruited and enrolled.

Participant flow — Overall Study
MilestoneDLBCL ArmFL Arm
Started10534
Completed6721
Not completed3813
Withdrew: Screen failure107
Withdrew: Death225
Withdrew: Lost to follow-up41
Withdrew: Adverse event10
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants With Administration-Associated Reactions (AARs)

AARs defined as all related adverse events (AEs) occurring within 24 hours of rituximab SC administration, including infusion/injection-related reactions (IIRRs), injection-site reactions, administration site conditions and all symptoms thereof.

Time frame:
Within 24 hours of each rituximab SC administration (maximum treatment duration up to 32 months for FL participants and up to 8 months for DLBCL participants)
Reported as:
Number · Percentage of Participants %
Percentage of Participants With Administration-Associated Reactions (AARs)
Percentage of Participants %DLBCL ArmFL ArmOverall Population
Blood And Lymphatic System Disorders, And Lymphatic System Disorders, Anaemia1.13.71.6
Blood And Lymphatic System Disorders, Leukopenia1.100.8
Blood And Lymphatic System Disorders, Thrombocytopenia1.100.8
General Disorders And Administration Site Conditions, Injection Site Erythema4.27.44.9
General Disorders And Administration Site Conditions, Injection Site, Injection Site Pain4.203.3
Nervous System Disorders, Burning Sensation2.101.6
Nervous System Disorders, Paraesthesia1.100.8
Skin And Subcutaneous Tissue Disorders, Erythema2.101.6
Skin And Subcutaneous Tissue Disorders, Dermatitis Allergic1.100.8
SecondaryEvent-Free Survival (EFS) as Assessed by Investigator According to International Working Group (IWG) Response Criteria

EFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first dose of SC) to first occurrence of progression or relapse, according to the IWG response criteria or other country standards, or initiation of a non-protocolspecified anti-lymphoma therapy or death, whichever occurs first.

Time frame:
From first dose of rituximab intravenous (IV) and SC until first occurrence of progression or relapse (up to end of induction treatment [Up to 53.8 Months])
Reported as:
Median · Months
Event-Free Survival (EFS) as Assessed by Investigator According to International Working Group (IWG) Response Criteria
MonthsDLBCL ArmFL ArmOverall
From first dose of rituximab IVNA (33.4 to NA)53.8 (32.6 to NA)53.8 (38.4 to NA)
From first dose of rituximab SCNA (32.7 to NA)45.5 (25.1 to NA)45.5 (33.5 to NA)
SecondaryProgression-Free Survival (PFS) as Assessed by Investigator According to IWG Response Criteria

PFS is defined as the time from first dose of rituximab (analysed using both first dose of IV and first dose of SC) to the first occurrence of progression or relapse, according to the IWG response criteria (Cheson et al. 1999) or other country standards, or death from any cause.

Time frame:
From first dose of rituximab IV and SC until first occurrence of progression or relapse (up to end of induction treatment [Up to 53.8 Months])
Reported as:
Median · Months
Progression-Free Survival (PFS) as Assessed by Investigator According to IWG Response Criteria
MonthsDLBCL ArmFL ArmOverall Population
From first dose of rituximab IVNA (33.4 to NA)53.8 (32.6 to NA)53.8 (38.4 to NA)
From first dose of rituximab SCNA (32.7 to NA)45.5 (25.1 to NA)44.5 (35.5 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from first dose of rirtuximab (analysed using both first dose of IV and first dose of SC) until death from any cause.

Time frame:
From first dose of rituximab IV and SC until death from any cause (up to end of induction treatment [Up to 51.1 Months])
Reported as:
Median · Months
Overall Survival (OS)
MonthsDLBCL ArmFL ArmOverall Population
From first dose of rituximab IV51.4 (50.4 to NA)NA (NA to NA)NA (NA to NA)
From first dose of rituximab SC51.4 (50.4 to NA)NA (NA to NA)NA (NA to NA)
SecondaryDisease-Free Survival (DFS) as Assessed by Investigator According to IWG Response Criteria

DFS will be assessed at the end of induction treatment in patients achieving CR/CRu and is defined as the period from the date of the initial CR/CRu until the date of relapse or death from any cause.

Time frame:
From the date of the initial complete response (CR)/complete response unconfirmed (CRu) until date of relapse or death from any cause (up to end of induction treatment [Up to 32.7 Months])
Reported as:
Median · Months
Disease-Free Survival (DFS) as Assessed by Investigator According to IWG Response Criteria
MonthsDLBCL ArmFL ArmOverall Population
Disease-Free Survival (DFS) as Assessed by Investigator According to IWG Response CriteriaNA (NA to NA)NA (19.7 to NA)NA (32.7 to NA)
SecondaryPercentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria

CR/CRu: Response assessments 4 - 6 weeks after the last dose of induction treatment will be based on the Investigator's assessment, completed according to the original International Working Group (IWG) response criteria for response assessment of lymphoma (Cheson et al. 1999).

Time frame:
From first dose of rituximab until first occurrence of progression or relapse (up to end of induction treatment [Up to 32 Months])
Reported as:
Number · Percentage
Percentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria
PercentageDLBCL ArmFL ArmOverall Population
Percentage of Participants With CR/CRu as Assessed by Investigator According to IWG Response Criteria74.2 (63.8 to 82.9)76.5 (50.1 to 93.2)74.5 (65.1 to 82.5)
SecondaryHealthcare Professional Questionnaire Score

Planned Healthcare Professional Questionnaiere was not collected during the study therefore no data to report

Time frame:
End of treatment (Month 24 for FL participants and Month 8 for DLBCL participants)

No measurements were reported for this outcome.

SecondaryPatient-Reported Rituximab Administration Questionnaire (RASQ) Score

The RASQ measures the overall participant satisfaction and is a 20-item questionnaire measuring the impact of the treatment administration on 5 domains: Physical Impact, Psychological Impact, Impact on Activities of Daily Living, Convenience, and Satisfaction. Each question's answer is chosen from 1 (minimum)-5(maximum score indicating less severity) score range. For each domain was scored using the following formula: Domain score = \[(Sum of completed item (question) responses / Number of completed items) - 1\] x 100 / (Maximum possible item response value - Minimum possible item response value) The final RASQ domains is calculated using the formula: RASQ domain score = (Mean of completed item responses - 1) x 25, scores ranging from 1-100 with higher scores indicative of more positive feelings toward therapy. Lower number representing lower satisfaction and higher is the higher satisfaction by the participants.

Time frame:
Up to 53.8 Months
Reported as:
Mean · Scores on a Scale
Patient-Reported Rituximab Administration Questionnaire (RASQ) Score
Scores on a ScaleDLBCL ArmFL ArmOverall Population
Patient-Reported Rituximab Administration Questionnaire (RASQ) Score70.5 ± 20.7669.2 ± 19.8370.2 ± 20.48

Adverse events

Collected over From first dose of rituximab IV and SC until death from any cause (up to end of induction treatment [up to 53.8 Months]). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DLBCL Arm22/95 (23.2%)11/95 (11.6%)58/95 (61.1%)
FL Arm5/27 (18.5%)8/27 (29.6%)12/27 (44.4%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventDLBCL ArmFL Arm
Febrile NeutropeniaBlood and lymphatic system disorders1/952/27
Cardiac Failure AcuteCardiac disorders0/951/27
GoitreEndocrine disorders0/951/27
DeathGeneral disorders2/951/27
Abscess LimbInfections and infestations0/951/27
Candida InfectionInfections and infestations0/951/27
Klebsiella BacteraemiaInfections and infestations0/951/27
Septic ShockInfections and infestations0/951/27
Fibula FractureInjury, poisoning and procedural complications0/951/27
Liver Function Test AbnormalInvestigations0/951/27
Most frequent other events
Showing 10 of 12
Most frequent other events
EventDLBCL ArmFL Arm
NeutropeniaBlood and lymphatic system disorders41/957/27
ParaesthesiaNervous system disorders14/955/27
AnaemiaBlood and lymphatic system disorders13/954/27
LeukopeniaBlood and lymphatic system disorders10/951/27
Mucosal InflammationGeneral disorders10/952/27
ThrombocytopeniaBlood and lymphatic system disorders9/952/27
DiarrhoeaGastrointestinal disorders8/950/27
Injection Site ErythemaGeneral disorders5/952/27
Aspartate Aminotransferase IncreasedInvestigations0/952/27
CoughRespiratory, thoracic and mediastinal disorders6/952/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)DLBCL ArmFL ArmTotal
Mean51.3 ± 13.7852.8 ± 12.6551.7 ± 13.48
Sex: Female, Male
Sex: Female, Male(Participants)DLBCL ArmFL ArmTotal
Female562278
Male491261
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DLBCL ArmFL ArmTotal
Not Hispanic or Latino15419
Hispanic or Latino000
Other742498
Not applicable as per local regulations16622
08

Study locations

13 sites
  • Hôpital Dorban CHU Annaba, Service d'Hématologie
    Annaba, 23000, Algeria
  • EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward
    Blida, 09000, Algeria
  • EHU Oran, Service d'Hématologie et de Thérapie Cellulaire
    Oran, 31000, Algeria
  • Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie
    Tizi Ouzou, 15000, Algeria
  • CHU 20 Aout Service D'Onco-Hematologie Pediatrique
    Casablanca, 20100, Morocco
  • Clinique AlMadina; Service hematologie
    Casablanca, 20340, Morocco
  • Centre Hospitalier Uni Ire de Marrakech; Oncologie-Hématologie
    Marrakech, 40000, Morocco
  • Hôpital d'enfants de Rabat - Service d'hémato-oncologie pédiatrique
    Rabat, 10090, Morocco
  • CHU Fattouma Bourguiba, Monastir; Service d'hématologie
    Monastir, 5000, Tunisia
  • CHU Hédi Chacker; Service d'hématologie
    Sfax, 3025, Tunisia
  • CHU Farhat Hached; Service d'hématologie
    Sousse, 4000, Tunisia
  • Aziza Othmana Hospital; Clinical Haematology
    Tunis, 1008, Tunisia
  • Hopital Militaire d'instruction de Tunis; Service d'hématologie
    Tunis, 1008, Tunisia
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2015 to primary completion in Jun 2021, 68 months.

Results were first posted in Nov 2024, 3 years 4 months after primary completion.

Of 41 industry-sponsored phase 3 interventional studies under Lymphoma, Non-Hodgkin, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 84. This study's 68 months is close to that.

Counting every sponsor, half of 58 studies reached it within 68 months; a quarter within 43 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2015
First posted
Apr 2, 2015
StartActual
Oct 13, 2015
Primary completionActual
Jun 30, 2021
CompletionActual
Jun 30, 2021
Results first posted
Nov 21, 2024
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02406092
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Apr 2, 2015
Start date
Oct 13, 2015
Primary completion
Jun 30, 2021
Completion
Jun 30, 2021
Results posted
Nov 21, 2024
Last update
Nov 21, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion